tirzepatide pancreatitis gallbladder warning label A 54-year-old woman with obesity (BMI 38 kg/m²) and type 2 diabetes is being considered for semaglutide. Five years ago she developed acute secondary to gallstones. She underwent laparoscopic cholecystectomy and GLP-1 Pancreatitis Risk: MHRA Warning

Important Safety Information : Tirzepatide carries a boxed warning for risk of thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Is tirzepatide maintenance dose safe to stay on indefinitely

The licensed pharmaceutical product Mounjaro is regulatorily and supply-chain distinct from research-grade tirzepatide powder, which is sold strictly for in vitro and non-human laboratory use and is not for human administration

For example, the prescribing information for semaglutide (Wegovy) also includes warnings about acute gallbladder disease, with cholelithiasis reported in 1.6% of patients receiving semaglutide versus 0.7% in the placebo group in clinical trials for weight management

If for any reason, the physician does not approve, you will be instantly refunded

The efficacy and safety of tirzepatide, with a special focus on cardiovascular safety, were investigated in the 52-week SURPASS-4 trial testing tirzepatide versus insulin glargine in adults with T2D and a high cardiovascular risk under inadequate glycemic control at baseline on one to three oral glucose-lowering medications (metformin, sulfonylurea, SGLT-2 inhibitor) (74)